Cardiol Therapeutics (CRDL) Projected to Post Earnings on Tuesday

Cardiol Therapeutics (NASDAQ:CRDL) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock opened at $1.15 on Friday. Cardiol Therapeutics has a 52 week low of $0.77 and a 52 week high of $3.12. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $1.04 and a 200-day moving average price of $1.31. The company has a market cap of $95.00 million, a PE ratio of -2.95 and a beta of 0.98.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a report on Wednesday, April 16th. RODMAN&RENSHAW upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw began coverage on shares of Cardiol Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $7.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $8.40.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.